We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
The most recent trading session ended with Vertex Pharmaceuticals (VRTX - Free Report) standing at $367.66, reflecting a +1.6% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw an increase of 0.27%.
Coming into today, shares of the drugmaker had gained 3.53% in the past month. In that same time, the Medical sector lost 5.22%, while the S&P 500 lost 3.95%.
Analysts and investors alike will be keeping a close eye on the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to go public on November 6, 2023. The company's earnings per share (EPS) are projected to be $3.94, reflecting a 1.75% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.49 billion, indicating a 6.5% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $14.61 per share and a revenue of $9.84 billion, indicating changes of -1.81% and +10.15%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Vertex Pharmaceuticals possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 24.77. This expresses a premium compared to the average Forward P/E of 16.86 of its industry.
We can also see that VRTX currently has a PEG ratio of 2.47. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.87 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
The most recent trading session ended with Vertex Pharmaceuticals (VRTX - Free Report) standing at $367.66, reflecting a +1.6% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw an increase of 0.27%.
Coming into today, shares of the drugmaker had gained 3.53% in the past month. In that same time, the Medical sector lost 5.22%, while the S&P 500 lost 3.95%.
Analysts and investors alike will be keeping a close eye on the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to go public on November 6, 2023. The company's earnings per share (EPS) are projected to be $3.94, reflecting a 1.75% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.49 billion, indicating a 6.5% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $14.61 per share and a revenue of $9.84 billion, indicating changes of -1.81% and +10.15%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Vertex Pharmaceuticals possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 24.77. This expresses a premium compared to the average Forward P/E of 16.86 of its industry.
We can also see that VRTX currently has a PEG ratio of 2.47. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.87 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.